Moderna expands its mrna pipeline with three new development programs

Mrna-1608 is a vaccine candidate against herpes simplex virus (hsv) mrna-1468 is a vaccine candidate against varicella-zoster virus (vzv) to reduce the rate of herpes zoster (shingles) mrna-4359 is a new checkpoint cancer vaccine cambridge, ma / accesswire / february 18, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that it is expanding its mrna pipeline with three new development programs. this announcement reflects the company's commitment to expanding its portfolio building on moderna's experience with spikevax®, its covid-19 vaccine.
MRNA Ratings Summary
MRNA Quant Ranking